Skip to main content
SpringerLink
Log in

Glucocorticoid-Induced Osteoporosis

  • Chapter
Nutrition and Bone Health

Part of the book series: Nutrition and Health ((NH))

Abstract

Chronic use of glucocorticoids (GCs) is the most common cause of secondary osteoporosis. We will review the current understanding of the clinical features, pathogenesis, and management of glucocorticoid-induced osteoporosis (GCOP), with emphasis on the nutritional aspects of the disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 249.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978; 16:238–255.

    Article  PubMed  CAS  Google Scholar 

  2. Kozower M, Veatch L, Kaplan MM. Decreased clearance of prednisolone, a factor in the develpment of corticoisteroid side effects. J Clin Endocrinol Metab 1974; 38:407–412.

    Article  PubMed  CAS  Google Scholar 

  3. Homik JE, Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26(5):1148–1157.

    PubMed  CAS  Google Scholar 

  4. Adachi J, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 2001; 44(1):202–211.

    Article  PubMed  CAS  Google Scholar 

  5. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339(5).292–299.

    Article  PubMed  CAS  Google Scholar 

  6. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-bind, placebo-controlled, parallelgroup study. Arthritis Rheum 1999; 42(11):2309–2318.

    Article  PubMed  CAS  Google Scholar 

  7. Gennari C. Glucocorticoids and bone. In: Peck WA, ed. Elsevier, Amsterdam, 1985, pp. 213–232.

    Google Scholar 

  8. Van Staa TP, Leufkens HGM, Abenhaim L. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6):993–999.

    Article  PubMed  Google Scholar 

  9. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4(2):137–141.

    Article  PubMed  CAS  Google Scholar 

  10. Luckert BP, Adams JS. Calcium and phosphorus homeostasis in man. Arch Intern Med 1976; 136:1249–1253.

    Article  Google Scholar 

  11. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32:151–156.

    Article  PubMed  CAS  Google Scholar 

  12. Bikle DD, Halloran BP, Fong L, Steinbach L, Shellito J. Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone. J Clin Endocrinol Metab 1993; 76(2):456–461.

    Article  PubMed  CAS  Google Scholar 

  13. Lund B, Storm TL, Lund B. Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment. Clin Rheumatol 1985; 4:143–149.

    Article  PubMed  CAS  Google Scholar 

  14. Slovik DM, Neer RM, Ohman JL, Lowell FC, Potts JT. Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin Endocrinol (Oxf) 1980; 12:243.

    Article  CAS  Google Scholar 

  15. Fucik RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 1975; 40:152–155.

    Article  PubMed  CAS  Google Scholar 

  16. Hodsman AB, Toogood JH, Jennings BH, Fraher LJ, Baskerville JC. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991; 72:530–540.

    Article  PubMed  CAS  Google Scholar 

  17. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981; 30:217–221.

    Article  PubMed  CAS  Google Scholar 

  18. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994; 9(7):1097–1105.

    Article  PubMed  CAS  Google Scholar 

  19. Collins EJ, Garrett ER, Johnston RL. Effect of adrenal steroids on radiocalcium metabolism in dogs. Metabolism 1962; 11:716–726.

    PubMed  CAS  Google Scholar 

  20. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis—a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87(9):4033–4041.

    Article  PubMed  CAS  Google Scholar 

  21. Lukert BP, Adams JS. Calcium and phosphorus homeostasis in man. Arch Intern Med 1976; 136:1249–1253.

    Article  PubMed  CAS  Google Scholar 

  22. Seeman E, Kumar R, Hunder GG, Scott M, Heath HI, Riggs BL. Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess. J Clin Invest 1980; 66:664–669.

    Article  PubMed  CAS  Google Scholar 

  23. Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 1989; 30:83–103.

    Article  CAS  Google Scholar 

  24. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 1979; 64:655–665.

    Article  PubMed  CAS  Google Scholar 

  25. Zerwekh JE, Emkey RD, Harris EDJ. Low-dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism. Arthritis Rheum 1984; 27:1050–1052.

    Article  PubMed  CAS  Google Scholar 

  26. Chesney RW, Mazess RB. Reduction of serum 1,25-dihydroxyvitamin D3 in children receiving glucocorticoids. Lancet 1978; 2:1123–1125.

    Article  PubMed  CAS  Google Scholar 

  27. Klein RG, Arnaud SB, Gallagher JC, DeLuca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977; 60:253–259.

    Article  PubMed  CAS  Google Scholar 

  28. Favus MJ, Walling MW, Kimberg DV. Effects of 1,25-dihydroxy-cholecalciferol in intestinal calcium transport in cortisone-treated rats. J Clin Invest 1973; 52:1680–1685.

    Article  PubMed  CAS  Google Scholar 

  29. Adams JS, Lukert BP. Effects of sodium restriction on 45-Ca and 22-Na transduodenal flux in cortico-steroid-treated rats. Miner Electrolyte Metab 1980; 4:216–226.

    CAS  Google Scholar 

  30. Hsueh AJ, Erickson GF. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 1978; 32:639–648.

    Article  PubMed  CAS  Google Scholar 

  31. Kimaru S, Rasmussen H. Adrenal glucocorticoids, adenine nucleotide translocation, and mitochondrial calcium accumulation. J Biol Chem 1977; 252:1217–1225.

    Google Scholar 

  32. Shultz TD, Kumar R. Effect of cortisol on [3H] 1,25-dihydroxyvitamin D3 uptake and 1,25-dihydroxyvitamin D3-induced DNA-dependent RNA polymerase activity in chick intestinal cells. Calcif Tissue Int 1987; 40:327–331.

    Article  Google Scholar 

  33. Morris HA, Need AG, O’Loughlin PD, Horowitz M, Bridges A, Nordin BEC. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990; 46:305–308.

    Article  PubMed  CAS  Google Scholar 

  34. Colette C, Monnier L, Pares Herbute N, Blotman F, Mirouze J. Calcium absorption in corticoid treated subjects—effects of a single oral dose of calcitriol. Horm Metab Res 1987; 19:335–338.

    Article  PubMed  CAS  Google Scholar 

  35. Chen TL, Cone CM, Morey-Holton E, Feldman D. 1-alpha,25-dihydroxyvitamin D3 receptors in cultured rat osteoblast-like cells. Glucocorticoid treatment increases receptor content. J Biol Chem 1983; 258:4350–4355.

    PubMed  CAS  Google Scholar 

  36. Charney AN, Kinsey MD, Myers L. Na-K-activated adenosine triphosphatase and intestinal electrolyte transport. Effect of adrenal steroids. J Clin Invest 1975; 56:653–660.

    Article  PubMed  CAS  Google Scholar 

  37. Shultz TD, Bollman S, Kumar R. Decreased intestinal calcium absorption in vivo and normal brush border membrane vesicle calcium uptake in cortisol-treated chickens: evidence for dissociation of calcium absorption from brush border vesicle uptake. Proc Natl Acad Sci USA 1982; 79:3542–3546.

    Article  PubMed  CAS  Google Scholar 

  38. Corradino RA, Fullmer CB. Positive cotranscriptional regulation of intestinal calbindin-D28K gene expression by 1,25-dihydroxyvitamin D3 and glucocorticoids. Endocrinology 1991; 128(2):944–950.

    Article  PubMed  CAS  Google Scholar 

  39. Aloia JF, Semla HM, Yeh JK. Discordant effects of glucocorticoids on active and passive transport of calcium in the rat duodenum. Calcif Tissue Int 1984; 36:327–331.

    Article  PubMed  CAS  Google Scholar 

  40. Reid DM, Kennedy NSJ, Smith MA, Tothill P, Nuki G. Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment. Br Med J 1982; 285:330–332.

    Article  CAS  Google Scholar 

  41. Nielsen HK, Thomsen K, Eriksen EF, Charles P, Storm TL, Mosekilde L. The effect of highdose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 1988; 4:105–113.

    PubMed  CAS  Google Scholar 

  42. Frieberg JM, Kinsella J, Sacktor B. Glucocorticoids increase the Na+-H+ exchange and decrease the Na+ gradient-dependent phosphate-uptake systems in renal brush border membrane vesicles. Proc Natl Acad Sci USA 1982; 79:4932–4936.

    Article  Google Scholar 

  43. Price PA, Otsuka JW, Poser JKN, Raman N. Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 1976; 73:1447–1451.

    Article  PubMed  CAS  Google Scholar 

  44. Lukert BP, Higgins JC, Stoskopf MM. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 1986; 62:1056–1058.

    Article  PubMed  CAS  Google Scholar 

  45. Hara K, Akiyama Y, Okkawa I, Tajima T. Bone 1993; 6:813–818.

    Article  Google Scholar 

  46. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975; 40:774–779.

    Article  PubMed  CAS  Google Scholar 

  47. Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab 1976; 43:622–629.

    Article  PubMed  CAS  Google Scholar 

  48. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104:648–651.

    PubMed  CAS  Google Scholar 

  49. Crilly RG, Cawood M, Marshall DH, Nordin BEC. Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 1978; 71:733–736.

    PubMed  CAS  Google Scholar 

  50. Reid IR, Frances JT, Pybus J, Ibbertson HK. Low plasma testosterone levels in glucocorticoidtreated male asthmatics. Br Med J 1985; 291:574.

    Article  CAS  Google Scholar 

  51. Montecucco C, Caporali R, Caprotti P, Caprotti M, Notario A. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 1992; 19(12):1895–1899.

    PubMed  CAS  Google Scholar 

  52. Kaufmann S, Jones KL, Wehrenberg WB, Culler FL. Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab 1988; 67(6): 1258–1261.

    Article  PubMed  CAS  Google Scholar 

  53. Gourmelen M, Girard F, Binoux M. Serum somatomedin/insulin-like growth factor (IGF) and IGF carrier levels in patients with Cushing’s syndrome or receiving glucocorticoid therapy. J Clin Endocrinol Metab 1982; 54:885–892.

    Article  PubMed  CAS  Google Scholar 

  54. Unterman TG, Phillips LS. Glucocorticoid effects on somatomedins and somatomedin inhibitors. J Clin Endocrinol Metab 1985; 61:618–626.

    Article  PubMed  CAS  Google Scholar 

  55. Chen TL, Feldman D. Glucocorticoid potentiation of the adenosine 3′,5′-monophosphate response to parathyroid hormone in cultured rat bone cells. Endocrinology 1978; 102:589–596.

    Article  PubMed  CAS  Google Scholar 

  56. Catherwood BD. 1,25-Dihydrocholecalciferol and glucocorticoid regulation of adenylate cyclase in an osteoblast-like cell line. J Biol Chem 1985; 160:736–743.

    Google Scholar 

  57. Wong GL. Basal activities and hormone responsiveness of osteoclast-like and osteoblast-like bone cells are regulated by glucocorticoids. J Biol Chem 1979; 254(14):6337–6340.

    PubMed  CAS  Google Scholar 

  58. Chen TL, Cone CM, Morey-Holton E, Feldman D. Glucocorticoid regulation of 1,25(OH)2-vitamin D3 receptors in cultured mouse bone cells. J Biol Chem 1982; 257:13564–13569.

    PubMed  CAS  Google Scholar 

  59. Morrison NA, Eisman JA. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 1993; 8(8):969–975.

    Article  PubMed  CAS  Google Scholar 

  60. Chen TL, Mallory JB, Hintz RL. Dexamethasone and 1,25(OH)2 vitamin D3 modulate the synthesis of insulin-like growth factor-I in osteoblast-like cells. Calcif Tissue Int 1991; 48:278–282.

    Article  PubMed  CAS  Google Scholar 

  61. Raisz LG, Fall PM. Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: interaction with cortisol. Endocrinology 1990; 126(2):1654–1659.

    Article  PubMed  CAS  Google Scholar 

  62. Sato K, Fujii Y, Kasono K, Saji M, Tsushima T, Shizume K. Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1-alpha in fetal mouse bones. Biochem Biophys Res Commun 1986; 138:618–624.

    Article  PubMed  CAS  Google Scholar 

  63. Marusic A, Raisz LG. Cortisol modulates the actions of interleukin-1 alpha on bone formation, resorption, and prostaglandin production in cultured mouse parietal bones. Endocrinology 1991; 129(5):2699–2706.

    Article  PubMed  CAS  Google Scholar 

  64. Canalis EM, McCarthy TL, Centrella M. Isolation and characterization of insulin-like growth factor I (somatomedin-C) from cultures of fetal rat calvariae. Endocrinology 1988; 122:22.

    Article  PubMed  CAS  Google Scholar 

  65. Kream BE, Petersen DN, Raisz LG. Cortisol enhances the anabolic effects of insulin-like growth factor I on collagen synthesis and procollagen messenger ribonucleic acid levels in cultured 21-day fetal rat calvariae. Endocrinology 1990; 126(3):1576–1583.

    Article  PubMed  CAS  Google Scholar 

  66. McCarthy TL, Centrella M, Canalis EM. Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells. Endocrinology 1990; 126(3):1569–1575.

    Article  PubMed  CAS  Google Scholar 

  67. Kream BE, LaFrancis PM, Fall PM, Feyen JHM, Raisz LG. Insulin-like growth factor binding protein-2 blocks the stimulatory effect of glucocorticoids on bone collagen synthesis. J Bone Miner Res 1992; 7(suppl 1):5100.

    Google Scholar 

  68. Centrella M, McCarthy TL, Canalis EM. Glucocorticoid regulation of transforming growth factor B1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Molec Cell Biol 1991; 11(9):4490–4496.

    PubMed  CAS  Google Scholar 

  69. Dietrich JW, Canalis EM, Maina DM, Raisz LG. Effect of glucocorticoids on fetal rat bone collagen synthesis in vitro. Endocrinology 1979; 104:715–721.

    Article  PubMed  CAS  Google Scholar 

  70. Puolijoki H, Liippo K, Herrala J, Salmi J, Tala E. Inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women. Bone 1992; 13:285–288.

    Article  PubMed  CAS  Google Scholar 

  71. Saami H, Jalkanen M, Hopsu-Havu VK. Effect of five anti-inflammatory steroids on collagen and glycoaminoglycan synthesis in vitro. Br J Dermatol 1980; 103:167–173.

    Article  Google Scholar 

  72. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983; 35:410–417.

    Article  PubMed  CAS  Google Scholar 

  73. Meunier PJ, Bressot C. Endocrine influences on bone cells and bone remodeling evaluated by clinical histomorphometry. Endocrinol Calcium Metabol 1982; 445–465.

    Google Scholar 

  74. Hofbauer LC, Gori FRBL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140(10):4382–4389.

    Article  PubMed  CAS  Google Scholar 

  75. Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 1998; 13(8):1283–1289.

    Article  PubMed  CAS  Google Scholar 

  76. Kukreja SC, Bowser EN, Hargis GK, Henderson WJ, Williams GA. Mechanisms of glucocorticoid-induced osteopenia: role of parathyroid glands. Proc Soc Exp Biol Med 1976; 152:358–361.

    PubMed  CAS  Google Scholar 

  77. Cooper MS, Bujalska I, Rabbit EH, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts. an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001; 16(6):1037–1044.

    Article  PubMed  CAS  Google Scholar 

  78. Plotkin LI, Weinstein RS, Parfitt AM, Roberson P, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104(10):1363–1374.

    Article  PubMed  CAS  Google Scholar 

  79. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326(22):1473–1478.

    Article  PubMed  CAS  Google Scholar 

  80. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long- term glucocorticoid therapy. Arch Intern Med 1990; 150(12):2545–2548.

    Article  PubMed  CAS  Google Scholar 

  81. Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1985; 24:892–898.

    Article  Google Scholar 

  82. Maldague B, Malghem J, DeDeuxchaisnes N. Radiologic aspects of glucocorticoid-induced bone disease. Adv Exp Med Biol 1984; 171:155–190.

    PubMed  CAS  Google Scholar 

  83. Tawn DJ, Watt I. Bone marrow scientography in the diagnosis of post-traumatic avascular necrosis of bone. Br J Radiol 1989; 62:790–795.

    Article  PubMed  CAS  Google Scholar 

  84. Askari A, Vignos PJJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976; 61:485–492.

    Article  PubMed  CAS  Google Scholar 

  85. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjomtorp P. Muscle and adipose tissue morphology and metabolism in Cushing’s syndrome. J Clin Endocrinol Metab 1988; 67:1122–1128.

    Article  PubMed  CAS  Google Scholar 

  86. Reid DM, Kennedy NSJ, Smith MA. Bone loss in rheumatoid arthritis and primary generalised osteoarthrosis: effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements. Br J Rheum 1986; 25:253–259.

    Article  CAS  Google Scholar 

  87. Jennings BH, Anderson KE, Johansson SA. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40:77–82.

    Article  PubMed  CAS  Google Scholar 

  88. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991; 2:60–61.

    Article  Google Scholar 

  89. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients on long-term inhaled steroids. Chest 1994; 105:1722–1727.

    Article  PubMed  CAS  Google Scholar 

  90. Laroche H, Arlet J, Mazieres B. Osteonecrosis of the femoral and humeral heads after intraarticular corticosteroid injections. J Rheumatol 1990; 17:549–551.

    PubMed  CAS  Google Scholar 

  91. Adachi J, Benson W, Bianchi F. Vitamin D and calcium in prevention of corticosteroid-induced osteoporosis: follow-up over three years. J Rheumatol 1996; 23:995–1000.

    PubMed  CAS  Google Scholar 

  92. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regressive. J Bone Miner Res 2002; 17:1512–1526.

    Article  PubMed  CAS  Google Scholar 

  93. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonehpritis. Calcif Tissue Int 2000; 66(2):123–128.

    Article  PubMed  CAS  Google Scholar 

  94. Inoue T, Sugiyama T, Matsubara T, Kawai S, Furukawa S. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with goucocorticoid and alfacalcidol. Endror J 2001; 48(1):11–18.

    CAS  Google Scholar 

  95. Adachi J, Bensen W, Hodsman AB. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 1993; 22:375–384.

    Article  PubMed  CAS  Google Scholar 

  96. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7(9):1063–1069.

    Article  PubMed  CAS  Google Scholar 

  97. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37(1499):1505.

    Google Scholar 

  98. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288(3):321–333.

    Article  Google Scholar 

  99. Amin S. LM, Simms RW FDT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis; A meta-regression. J Bone Miner Res 2002; 17:1512–1526.

    Article  PubMed  CAS  Google Scholar 

  100. Mulder H, Smelder HAA. Effect of cyclical etidronate regimen on prophylaxis of bone loss of glucocorticoid (prednisone) therapy in postmenopausal women. J Bone Miner Res 1992; 7:S331.

    Google Scholar 

  101. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-l-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; 1:143–146.

    Article  PubMed  CAS  Google Scholar 

  102. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoidinduced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, and infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16:104–112.

    Article  PubMed  CAS  Google Scholar 

  103. Wallach S, Reid DM, Hughes RA, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67:277–285.

    Article  PubMed  CAS  Google Scholar 

  104. Reid DM, Hughes RA, Laan R, Sacco-Gibson NA, Wenderoth DH. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15(6):1006–1012.

    Article  PubMed  CAS  Google Scholar 

  105. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998; 102:1627–1633.

    Article  PubMed  CAS  Google Scholar 

  106. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoidinduced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 27:944–951.

    Google Scholar 

  107. Canalis EM, Delaney AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966:73–81.

    Article  PubMed  CAS  Google Scholar 

  108. Bellido T, Plotkin LI, Han L, Manolagas SC, Jilka RL. PTH prevents glucocorticoid-induced apoptosis of osteoblasts and osteoclasts in vitro: direct interference with a private death path-way upstream from caspase-3. Bone 1998; 23:S518.

    Google Scholar 

  109. Meunier PJ, Birancon D, Chavassieux P. Treatment with fluoride: bone histomorphometric findings. In: Osteoporosis Christiansen C, Johansen JS, Riis BJ, eds. Osteopress. Copenhagen, 1987, pp. 824–828.

    Google Scholar 

  110. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86:265–272.

    Article  PubMed  CAS  Google Scholar 

  111. Gray RES, Doherty SM, Galloway J, Coulton L, Debroe M, Kanis JA. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991; 34(3):287–295.

    Article  PubMed  CAS  Google Scholar 

  112. Canalis EM, Avioli LV. Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells. Bone Miner Res 1992; 7(9):1085–1092.

    Article  CAS  Google Scholar 

  113. O’Connell SL, Tresham J, Fortune CL. Effects of prednisolone and deflazacort on osteocalcin metabolism in sheep. Calcif Tissue Int 1993; 53:117–121.

    Article  PubMed  Google Scholar 

  114. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Molec Endocrinol 1997; 11(9):1245–1253.

    Article  CAS  Google Scholar 

  115. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing’s syndrome. Clin Endocrinol 1992; 36:229–234.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Barbara P. Lukert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Dermatology, Physiology, and Biophysics, Boston University School of Medicine, Boston, MA, USA

    Michael F. Holick PhD, MD

  2. Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA

    Bess Dawson-Hughes MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lukert, B.P. (2004). Glucocorticoid-Induced Osteoporosis. In: Holick, M.F., Dawson-Hughes, B. (eds) Nutrition and Bone Health. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-740-6_36

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-740-6_36

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-451-7

  • Online ISBN: 978-1-59259-740-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation